Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.31
+3.98 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
38
39
Next >
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
December 11, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
December 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
December 10, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
11 Analysts Have This to Say About Regeneron Pharmaceuticals
November 28, 2023
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
November 17, 2023
Via
Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
November 16, 2023
Via
Benzinga
3 biotech powerhouses poised to thrive amid sector rebound
December 08, 2023
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
Via
MarketBeat
Topics
ETFs
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
December 08, 2023
Regeneron has been an excellent investment in recent years. Can that trend continue?
Via
The Motley Fool
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
December 07, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
December 07, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Regeneron Pharmaceuticals Stands With Analysts
November 09, 2023
Via
Benzinga
2 Soaring Stocks to Buy and Hold
November 09, 2023
Both of these companies crushed earnings season.
Via
The Motley Fool
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
December 06, 2023
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
December 02, 2023
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
December 01, 2023
Via
Benzinga
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
November 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotech And Healthcare Portfolio Playbook For December 2023/24
November 27, 2023
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.
Via
Talk Markets
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
November 27, 2023
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.
Via
Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
November 27, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...
Via
Benzinga
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
November 27, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
November 16, 2023
Via
Benzinga
Regeneron Announces Investor Conference Presentation
November 15, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
November 13, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.
Via
InvestorPlace
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
November 06, 2023
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
Via
Investor's Business Daily
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
November 06, 2023
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during...
Via
Benzinga
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review
November 03, 2023
Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than-
Via
Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.